Down-regulated expression of RhoA in human conventional renal cell carcinoma

Anticancer Research

Volumn 28, Issue 4 B, 2008, Pages 2039-2043

  Pu, Yeong Shiau ^a   Wang, Chuang Wei ^b   Liu, Guang Yaw ^c   Kuo, Yi Zih ^b   Huang, Chao Yuan ^a   Kang, Wang Yi ^b   Shun, Chia Tung ^a   Lin, Chia Chi ^d   Wu, Wen Jeng ^b   Hour, Tzyh Chyuan ^b,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

GTPase; Immunohistochemistry; Real time PCR; Renal cell carcinoma

Indexed keywords

MESSENGER RNA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

CARCINOMA, RENAL CELL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER;

EID: 49049084637     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Escudier B: Advanced renal cell carcinoma: current and emerging management strategies. Drugs 67: 1257-1264, 2007.
2. Larkin JM, Chowdhury S and Gore ME: Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat Clin Pract Oncol 4: 470-479, 2007.
3. Laber DA: Risk factors, classification, and staging of renal cell cancer. Med Oncol 23: 443-454, 2006.
4. Unnithan J and Rini BI: The role of targeted therapy in metastatic renal cell carcinoma. Scientific World J 7: 800-807, 2007.
5. Ficarra V, Galfano A, Mancini M, Martignoni G and Artibani W: TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 8: 554-558, 2007.
6. Aaltomaa S, Lipponen P, la-Opas M, Eskelinen M and Syrjanen K: Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol 31: 350-355, 1997.
7. Merseburger AS, Hennenlotter J, Simon P, Kruck S, Koch E, Horstmann M, Kuehs U, Kufer R, Stenzl A and Kuczyk MA: Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 25: 1901-1908, 2005.
8. Sejima T and Miyagawa I: Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur Urol 35: 242-248, 1999.
9. Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature 420: 629-635, 2002.
10. Embade N, Valeron PF, Aznar S, Lopez-Collazo E and Lacal JC: Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production. Mol Biol Cell 11: 4347-4358, 2000.
11. Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA and Collard JG: Rho family proteins in cell adhesion and cell migration. Eur J Cancer 36: 1269-1274, 2000.
12. Wu M, Wu ZF and Merajver SD: Rho proteins and cell-matrix interactions in cancer. Cells Tissues Organs 185: 100-103, 2007.
13. Dreissigacker U, Mueller MS, Unger M, Siegert P, Genze F, Gierschik P and Giehl K: Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal 18(8): 1156-1168, 2006.
14. Hirsch DS and Wu WJ: Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. Expert Rev Anticancer Ther 7: 147-157, 2007.
15. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83: 861-870, 2003.
16. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y and Fan D: Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res 10:6239-6247, 2004.
17. Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y and Yoshida K: Overexpression of RhoA, Rac1, and Cdc42 GTPases are associated with progression in testicular cancer. Clin Cancer Res 10: 4799-4805, 2004.
18. Ellenbroek SI and Collard JG: Rho GTPases: functions and association with cancer. Clin Exp Metastasis 24: 657-672, 2007.
19. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
20. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Manual 6th ed. New York, Springer-Verlag, pp. 323-328, 2002.
21. Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med 353: 2477-2490, 2005.
22. Shiokawa S, Iwashita M, Akimoto Y, Nagamatsu S, Sakai K, Hanashi H, Kabir-Salmani M, Nakamura Y, Uehata M and Yoshimura Y: Small guanosine triphospatase RhoA and Rho-associated kinase as regulators of trophoblast migration. J Clin Endocrinol Metab 87: 5808-5816, 2002.
23. Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142, 2002.
24. Aznar S and Lacal JC: Rho signals to cell growth and apoptosis. Cancer Lett 165: 1-10, 2001.
25. del PL, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C and Lacal JC: Rho proteins induce metastatic properties in vivo. Oncogene 15: 3047-3057, 1997.
26. Jimenez B, Arends M, Esteve P, Perona R, Sanchez R, Cajal S, Wyllie A and Lacal JC: Induction of apoptosis in NIH3T3 cells after serum deprivation by Overexpression of rho-p21, a GTPase protein of the ras superfamily. Oncogene 10: 811-816, 1995.